Results 1 to 10 of about 97,265 (298)

Thyroid Eye Disease

Life, 2022
Thyroid eye disease (TED), an autoimmune inflammatory disorder of the orbit, presents with a potential array of clinical sequelae. The pathophysiology behind TED has been partially characterized in the literature.
Ramy Rashad, Raquel Pinto, Emily Li, Mahsa Sohrab, Alberto G. Distefano   +4 more
doaj   +5 more sources

Horizontal eye position in thyroid eye disease: a retrospective comparison with normal individuals and changes after orbital decompression surgery. [PDF]

PLoS ONE, 2014
To compare horizontal eye positions between proptotic thyroid eye disease patients and normal individuals, and to examine positional changes after orbital decompression surgery in thyroid eye disease patients.The present case-controlled and retrospective
Yasuhiro Takahashi, Hirohiko Kakizaki
doaj   +3 more sources

Graves’ ophthalmopathy – thyroid eye disease

Journal of Education, Health and Sport, 2019
Graves’ disease (GD) is an autoimmune disorder that affects thyroid. It is caused by antibody, named thyroid-stimulating immunoglobulin (TIS) that acts like thyroid stimulating hormone (TSH), resulting in thyroid hormone overproduction – condition called
Dagna Siedlecka, Wojciech Micał, Ewa Krzewicka-Romaniuk, Rashed Mustafa Nazzal   +3 more
doaj   +5 more sources

Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report [PDF]

Thyroid Research
Background Rituximab, an anti-CD20 monoclonal antibody that depletes B-cells, is a potential second-line treatment for moderate-to-severe active Thyroid Eye Disease that is resistant to steroids.
Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller   +6 more
doaj   +2 more sources

Clinical characteristics of thyroid eye disease and expression profile of peripheral blood immune cells [PDF]

Scientific Reports
This study included patients with thyroid eye disease (n = 81) and Graves’ disease (n = 165) for a cross-sectional study. Then, peripheral blood mononuclear cells (PBMCs) were collected from patients with thyroid eye disease (n = 5), Graves’ disease (n = 
Hongli Lin, Honghong Duan, Jingyi Zheng, Zhengrong Jiang, Yajing Xu, Huibin Huang   +5 more
doaj   +2 more sources

Quantification of enlargement of the levator palpebrae superioris muscle in thyroid eye disease. [PDF]

Int Ophthalmol
Hains L, Rana K, Almater A, Patel S, Selva D.   +4 more
europepmc   +3 more sources

No retinopathy after orbital irradiation in patients with thyroid eye disease - a follow up study. [PDF]

Front Endocrinol (Lausanne)
Makhoul S, Aranyosi JK, Csiki E, Urbancsek H, Nagy EB, Erdei A, Fodor M, Kovacs A, Nagy EV, Ujhelyi B.   +9 more
europepmc   +3 more sources

Advancing the Therapeutic Frontier in Thyroid Eye Disease. [PDF]

touchREV Endocrinol
Mohammadi SO, Ray C.
europepmc   +3 more sources

Thyroid eye disease [PDF]

QJM, 2015
A 72-year-old man presented to the emergency with dizziness and progressive double vision for one month. He was diagnosed as Graves’ disease at another medical center at his age of 60, and he had received antithyroid medication with restoration of euthyroidism. There had been no ocular abnormality until 6 years ago, when proptosis occurred. In addition,
H-J, Hsu, C-K, Hsu, T-S, Chen, C-H, Hsu
  +5 more sources

Orbital inflammatory disease following mRNA SARS‐CoV‐2 vaccine

Clinical Case Reports, 2022
A 65‐year‐old woman reported orbital symptoms two days after her first dose and presented exacerbation of signs after the second dose of BNT162b2 mRNA vaccine.
Solange Grunenwald, Gabriel Lethellier, Philippe Imbert, Céline Dekeister, Philippe Caron   +4 more
doaj   +1 more source